Immuneering (IMRX) H.C. Wainwright 28th Annual Global Investment Conference summary
Event summary combining transcript, slides, and related documents.
H.C. Wainwright 28th Annual Global Investment Conference summary
16 Sep, 2026Current clinical progress and pipeline
Phase III trial of third-generation MEK inhibitor atebimetinib is underway in first-line pancreatic cancer, with over 40 sites active and top-line readout expected mid-2028.
Multiple ongoing studies include a phase II lung cancer trial in combination with cemiplimab, with first patient dosing expected by year-end and top-line results by end of next year.
Phase II data in first-line pancreatic cancer showed 84% of patients were weight stable or gained weight at three months, a significant outcome in this population.
Additional phase II arms are ongoing, including combinations with FOLFIRINOX, with further data to be shared in the future.
Differentiation and mechanism of atebimetinib
Atebimetinib is a third-generation MEK inhibitor designed to address toxicity issues seen in earlier generations, using a novel Deep Cyclic Inhibition approach.
Demonstrates improved tolerability, with significantly reduced rates of rash and diarrhea compared to previous MEK inhibitors.
Mechanistically, it blocks the CRAF bypass, enabling efficacy in RAS mutant disease, and is distinct from first- and second-generation MEK inhibitors.
Preclinical data suggest strong synergy when combined with mutation-specific RAS inhibitors.
Key clinical data and patient outcomes
Phase II study in first-line pancreatic cancer showed a median overall survival (OS) of 17.3 months, a result not achieved by any RAS inhibitor in this setting.
Only two Grade 3 treatment-related adverse events (anemia and neutropenia) occurred in more than 10% of patients, both linked to chemotherapy, indicating high tolerability.
60% of patients were able to proceed to second-line treatment, compared to 40% in the standard of care MPACT study.
84% of patients were weight stable or gained weight, supporting better quality of life and survival.
Latest events from Immuneering
- Pancreatic data and new CLDN18.2 and ATC studies advance atebimetinib development.IMRX
Study update - MAPKeeper-301 enrollment is ahead of schedule, with top-line data guided for mid-2028.IMRX
3rd Annual Guggenheim Healthcare Innovation Conference - Atebimetinib + mGnP showed 86% 9-month OS; a randomized Phase 3 trial is planned.IMRX
Study update - Higher trial spending lifted losses as runway guidance moved to Q4 2028.IMRX
Q3 2026 - Atebimetinib nearly doubles survival in first-line pancreatic cancer with superior tolerability.IMRX
12th Annual Cantor Fitzgerald Global Healthcare Conference - Pivotal trial for atebimetinib advanced, with strong interim data and cash runway into 2029.IMRX
Q2 2026 - Atebimetinib shows strong survival and tolerability in pancreatic cancer, with pivotal phase III underway.IMRX
25th Annual Needham Virtual Healthcare Conference - Atebimetinib plus mGnP achieved 94% 6-month OS and strong tolerability in pancreatic cancer.IMRX
Study Update - IMM-1-104 achieved 43% ORR and 86% DCR with strong tolerability in first-line pancreatic cancer.IMRX
Study Result